Table 3.
Doc.\Pred. TAX-327 Tannock et al.2 | Doc.\EMP\Pred. SWOG 9906 Petrylak et al.3 | Doc\EMP\Pred.\Bev CALGB 90006 Picus et al. | |
---|---|---|---|
Adverse Events Grade 3,4 or 5 | |||
Neutropenia | 32% | 12.5% | 69% |
Febrile neutropenia | 3% | 5% | 4% |
Infection | - | 13.6% | 16% |
Fatigue | 5% | - | 25% |
Pain | - | 11% | 14% |
Thrombosis\Embolism | - | 6% | 9% |
Hemorrhage | - | 4% | 1% |
Death, treatment related | 0.3% | 2.4% | 3.8% |
Clinical Outcomes | |||
50% PSA Decline | 32% | 12.5% | 75% |
CR\PR –measurable disease | 12% | 17% | 59% |
Progression Free Survival | ~8.2 months | 6.3 months | 8.0 months |
Overall Survival | 19.2 months | 17.5 months | 24 months |